U.S. FDA approves Akebia's anemia drug
28/03/2024 24:43
March 27 (Reuters) - The U.S. Food and Drug Administration approved Akebia Therapeutics' AKBA.O drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday. (Reporting by Pratik Jain, Vaibhav Sadhamta and Mrinmay Dey in Bengaluru; Editing by Subhranshu Sahu) ((Pratik.Jain@thomsonreuters.com;))
Recent news on Akebia Therapeutics
See all newsAkebia Q1 revenue falls, net income misses analyst estimates on higher expenses
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule